AGC Biologics began its cell therapy process development and clinical manufacturing services on July 1, 2025, at its Yokohama Technical Center in Japan.
AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs).
GenSight Biologics recently announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ, the Company’s gene therapy candidate product to CDMO Catalent.
Exclusive licensing and R&D collaboration between Hovione and Firstgene.
Gemma Biotherapeutics (GemmaBio), a new therapeutics company founded by gene therapy pioneer Jim Wilson, recently announced the completion of a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives.
Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a US clinical-stage biopharmaceutical company developing donor-derived CAR-T cell therapies, in a deal valued at approximately $1.5 billion.
Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
The minicircle has emerged as a Next Generation Gene Vector and as a promising tool in the field of gene delivery and therapeutic applications. This overview aims to cover the characteristics, production methods, and potential applications of minicircle DNA.
Keen Vision Acquisition Corp. (KVAC) and Medera, a clinical-stage biotechnology company, have entered into a merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company will operate under the name Medera.
Ori Biotech a cell and gene therapy (CGT) manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform.
Cell and gene therapies (CGTs) present a revolutionary approach to the pharmaceutical industry. However, several complexities do arise on a logistical spectrum that diverge from those of traditional pharmaceuticals.
